InNexus to Develop SuperAntibody for Treatment of Coronary Heart Disease (Plaque)
InNexus Biotechnology, Inc. is pleased to announce that it has received approval from the TSX Venture Exchange for the acquisition of monoclonal antibodies and related intellectual property from ImmPheron Inc. of Lexington, Kentucky. InNexus intends to initiate the product development of the S(T15) SuperAntibody as its lead SuperAntibody product as it believes that S(T15) represents, potentially, the most efficacious product currently in the marketplace or in development for reducing plaque in the treatment of Coronary Heart Disease ("CHD").
Dr. A. Charles Morgan, President, said, "I'm extremely proud of the progress we have made with our S(T15) SuperAntibody product for the treatment of CHD. We are on track for clinical development and believe this SuperAntibody represents the best opportunity for treatment of plaque."
A major factor of CHD is the build-up of plaque. When the coronary arteries become narrowed or clogged by fat and cholesterol deposits, the heart is starved of needed blood supply. Recent studies show the number of total prevalent cases of CHD will be approximately 217 million in 2012. The market for CHD products is expected to reach $15 billion in 2007, growing to $23 billion in 2012. Current treatment is based on the use of statins, which lower cholesterol levels and represent over $10 billion in annual sales. Statins have demonstrated only a 1% reduction of plaque in arteries. Recently Atherogenics Inc. (NASDAQ: AGIX) announced a novel anti-inflammatory agent that they claim demonstrated a 3.8% reduction in plaque in clinical studies.
The treatment approach and distinctive mechanism of action of the S(T15) SuperAntibody has been demonstrated in animal models to reduce plaque by 20- 25%. There is no guarantee that such results will translate into clinical efficacy, though the same animal model used for evaluation has been used for evaluation of other anti-plaque drugs.
InNexus and ImmPheron have filed for intellectual property protection for the use of this SuperAntibody for the treatment of CHD. InNexus believes its intellectual property positioning of SuperAntibody Technology and specific claims for product indications will enable it to fully protect this treatment approach for CHD and enable it ultimately to co-develop or out-license the product to partners.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
